Table 1.

Analyzed CSF Biomarkers and Corresponding Patients’ Data.

	CSF Aβ42			CSF Aβ42/40			CSF tTau			CSF pTau
	APOE ε4 carrier	Non APOE ε4 carrier	p	APOE ε4 carrier	Non APOE ε4 carrier	p	APOE ε4 carrier	Non APOE ε4 carrier	p	APOE ε4 carrier	Non APOE ε4 carrier	p
Excluded cases
Within borderline  cutoff zone  (±10%)	16	14		12	10		16	11		17	14
Included cases
Concordant  (n) (%)	12 (31.6)a	46 (79.3)b	<.0001	25 (59.5)a	54 (87.1)b	.0020	32 (84.2)	57 (93.4)	.1761	35 (94.6)	56 (96.6)	.6414
Discordant  (n) (%)	26 (68.4)a	12 (20.7)b		17 (40.5)a	8 (12.9)b		6 (15.8)	4 (6.8)		2 (5.4)	2 (3.4)
Age (years)	68.4 ± 8.6	67.7 ± 9.6	.5693	69.8 ± 10.1	66.6 ± 10.2	.1159	68.2 ± 10.8	66.3 ± 10.0	.3782	70.7 ± 10.7	67.5 ± 10.0	.1536
Females	25	32	.3958	23	35	>.9999	22	33	.8357	20	30	.0366
Males	13	26		19	27		16	28		17	28

Note. Concordant and discordant cases are shown as absolute numbers and percentage. Significance for age differences were analyzed using t test, concordance, and gender was analyzed using Fisher’s exact test. APOE = apolipoprotein E; CSF = cerebrospinal fluid; Aβ = amyloid-beta; Aβ₄₂ = Aβ 1-42; Aβ_42/40 = Aβ₄₂ to Aβ 1-40 ratio; tTau = total tau; p181Tau = phosphorylated 181tau.

^aFisher’s exact test comparing concordance for Aβ₄₂ and Aβ_42/40 in APOE ε4 carriers with p = .0147 and non APOE ε4 carriers.

^bp = .3285.